450 related articles for article (PubMed ID: 28089416)
1. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
5. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
6. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
7. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T; Hwang JK; George DJ; Pal SK
Cancer Treat Res Commun; 2020; 24():100183. PubMed ID: 32563923
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment strategies in clear-cell metastatic renal cell carcinoma.
van Spronsen DJ; de Weijer KJ; Mulders PF; De Mulder PH
Anticancer Drugs; 2005 Aug; 16(7):709-17. PubMed ID: 16027518
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for kidney cancer in urologic practice.
Haas NB; Uzzo RG
Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
11. Emerging immunotherapies for renal cell carcinoma.
Escudier B
Ann Oncol; 2012 Sep; 23 Suppl 8():viii35-40. PubMed ID: 22918926
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
Ambrosetti D; Coutts M; Paoli C; Durand M; Borchiellini D; Montemagno C; Rastoin O; Borderie A; Grepin R; Rioux-Leclercq N; Bernhard JC; Pagès G; Dufies M
BJU Int; 2022 Jan; 129(1):80-92. PubMed ID: 34107167
[TBL] [Abstract][Full Text] [Related]
14. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for kidney cancer: status quo and the future.
Bedke J; Stühler V; Stenzl A; Brehmer B
Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
[TBL] [Abstract][Full Text] [Related]
16. The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma.
Hwang C; Heath EI
J Clin Oncol; 2014 Mar; 32(8):729-34. PubMed ID: 24516012
[No Abstract] [Full Text] [Related]
17. Perspectives in drug development for metastatic renal cell cancer.
Basu B; Eisen T
Target Oncol; 2010 Jun; 5(2):139-56. PubMed ID: 20689997
[TBL] [Abstract][Full Text] [Related]
18. [New drugs for metastatic kidney cancer].
Doehn C
Aktuelle Urol; 2008 Jan; 39(1):41-52. PubMed ID: 18228187
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
20. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
